Cellectis to present clinical data for leukemia and lymphoma therapies at EHA congress

Cellectis, a clinical-stage biotechnology company, will present clinical data on its lasme-cel and eti-cel therapies at the European Hematology Association (EHA) annual congress in Stockholm, Sweden, from June 11–14, 2026.

The company will deliver an oral presentation on the Phase 1 dataset from the BALLI-01 clinical trial evaluating lasme-cel, a CD22-directed allogeneic CAR-T therapy, in patients with relapsed or refractory CD22-positive B-cell acute lymphoblastic leukemia (r/r B-ALL). These patients have largely exhausted treatment options and have faced a poor prognosis, often after prior therapies including autologous CD19 CAR-T. The data demonstrate a promising safety profile and response rates, forming the basis for the ongoing pivotal Phase 2 program. "The depth of response we observed offers hope for these patients," said Adrian Kilcoyne, Chief Medical Officer at Cellectis.

Additionally, Cellectis will present a poster on the NATHALI-01 study evaluating eti-cel in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (r/r B-NHL). This preliminary analysis explores the relationship between alemtuzumab exposure, cellular expansion of eti-cel, cytokine dynamics, and clinical outcomes. The findings aim to provide early mechanistic insights for optimizing the lymphodepletion regimen for this dual-targeting CD20/CD22 allogeneic CAR T-cell product.

Phase 1 clinical data from both the BALLI-01 and NATHALI-01 trials are planned for disclosure in the fourth quarter of 2026. Cellectis also plans to share the first interim analysis of its pivotal Phase 2 program later this year. Abstracts are published on the EHA website, and presentations will be available on Cellectis' website starting June 11, 2026.